- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
446
Companies which are more than 50% undervalued based on analyst price target.
446 companies
Acumen Pharmaceuticals
Market Cap: US$107.2m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$1.73
7D
21.8%
1Y
-27.0%
Coya Therapeutics
Market Cap: US$102.0m
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
COYA
US$6.10
7D
11.1%
1Y
-16.0%
Insight Molecular Diagnostics
Market Cap: US$95.9m
Operates as a precision diagnostics company in the United States and internationally.
IMDX
US$3.35
7D
0.6%
1Y
15.9%
Immunic
Market Cap: US$95.0m
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
IMUX
US$0.98
7D
4.2%
1Y
-39.2%
InflaRx
Market Cap: US$93.5m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$1.58
7D
21.5%
1Y
1.3%
Metagenomi
Market Cap: US$93.5m
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
MGX
US$2.65
7D
15.7%
1Y
31.2%
Pliant Therapeutics
Market Cap: US$92.1m
A biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
PLRX
US$1.52
7D
0%
1Y
-86.8%
Adagene
Market Cap: US$91.4m
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
ADAG
US$1.98
7D
1.0%
1Y
-10.4%
Context Therapeutics
Market Cap: US$89.7m
A biopharmaceutical company, develops products for the treatment of solid tumors.
CNTX
US$1.10
7D
20.9%
1Y
-42.7%
Nutriband
Market Cap: US$88.2m
Develops a portfolio of transdermal pharmaceutical products in the United States.
NTRB
US$7.43
7D
2.3%
1Y
23.8%
Champions Oncology
Market Cap: US$88.1m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.30
7D
0%
1Y
31.5%
Quince Therapeutics
Market Cap: US$88.1m
A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
QNCX
US$1.65
7D
2.5%
1Y
109.3%
Assertio Holdings
Market Cap: US$87.9m
A pharmaceutical company, provides various products to patients in the United States.
ASRT
US$0.91
7D
2.8%
1Y
-20.2%
Werewolf Therapeutics
Market Cap: US$87.8m
A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.
HOWL
US$2.05
7D
-1.0%
1Y
1.0%
Equillium
Market Cap: US$87.5m
A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
EQ
US$1.33
7D
-11.3%
1Y
53.8%
Entera Bio
Market Cap: US$85.8m
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs.
ENTX
US$1.90
7D
4.4%
1Y
1.6%
BioStem Technologies
Market Cap: US$84.7m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.96
7D
-0.2%
1Y
-49.9%
Vaxart
Market Cap: US$84.5m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.
VXRT
US$0.36
7D
-2.0%
1Y
-55.4%
Fortress Biotech
Market Cap: US$83.3m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.75
7D
-29.7%
1Y
68.7%
MindWalk Holdings
Market Cap: US$81.7m
Operates as a bio-native AI company.
HYFT
US$1.69
7D
-6.1%
1Y
170.4%
Unicycive Therapeutics
Market Cap: US$81.6m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$4.62
7D
14.9%
1Y
23.6%
Prelude Therapeutics
Market Cap: US$81.5m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.47
7D
-2.0%
1Y
-26.5%
CEL-SCI
Market Cap: US$81.2m
A clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
CVM
US$10.47
7D
17.0%
1Y
-67.7%
Pelthos Therapeutics
Market Cap: US$81.0m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$28.00
7D
-17.2%
1Y
339.3%
Cibus
Market Cap: US$80.8m
An agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.
CBUS
US$1.44
7D
10.8%
1Y
-52.8%
Clene
Market Cap: US$80.7m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$10.51
7D
78.7%
1Y
98.3%
NRx Pharmaceuticals
Market Cap: US$79.2m
A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.
NRXP
US$3.27
7D
10.8%
1Y
112.3%
X4 Pharmaceuticals
Market Cap: US$78.1m
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
XFOR
US$3.48
7D
0.6%
1Y
-81.3%
Connect Biopharma Holdings
Market Cap: US$77.5m
A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.
CNTB
US$1.49
7D
-5.7%
1Y
5.7%
Sutro Biopharma
Market Cap: US$76.5m
Operates as a oncology company.
STRO
US$0.91
7D
2.5%
1Y
-74.8%
CervoMed
Market Cap: US$75.6m
A a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
CRVO
US$8.70
7D
5.1%
1Y
-39.4%
OKYO Pharma
Market Cap: US$74.5m
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
OKYO
US$2.05
7D
-6.0%
1Y
91.6%
PMV Pharmaceuticals
Market Cap: US$73.1m
A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
PMVP
US$1.44
7D
-2.7%
1Y
-5.9%
Plus Therapeutics
Market Cap: US$72.6m
A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
PSTV
US$0.73
7D
18.5%
1Y
-43.8%
Artiva Biotherapeutics
Market Cap: US$72.1m
A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
ARTV
US$2.95
7D
-0.3%
1Y
-81.4%
MiNK Therapeutics
Market Cap: US$69.9m
A clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
INKT
US$15.02
7D
7.6%
1Y
109.4%